STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Profusa, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Profusa, Inc. (PFSA) disclosed it received a Nasdaq notice on October 27, 2025 for failing to maintain the Nasdaq Global Market’s minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 over 30 consecutive business days through October 24, 2025.

The notice does not immediately affect trading, and PFSA will continue to trade on the Nasdaq Global Market during the compliance period. Under Nasdaq rules, Profusa has 180 calendar days, until April 27, 2026, to regain compliance. If its MVPHS closes at or above $15,000,000 for 10 consecutive business days before that date, Nasdaq will confirm compliance.

If compliance is not regained by April 27, 2026, Nasdaq may initiate delisting. Profusa could appeal or consider transferring to the Nasdaq Capital Market, subject to meeting that market’s standards. The company said it will monitor MVPHS and evaluate available options within the compliance period.

Positive
  • None.
Negative
  • Received Nasdaq Global Market MVPHS deficiency notice; cure deadline April 27, 2026 with 10 consecutive business days at or above $15,000,000.

Insights

Nasdaq MVPHS deficiency creates delisting risk if not cured by April 27, 2026.

Profusa fell below Nasdaq Global Market’s MVPHS threshold of $15,000,000 for 30 consecutive business days, triggering an Item 3.01 notice. Shares continue trading during the cure period, so there is no immediate trading halt or removal.

The compliance pathway is mechanical: achieve an MVPHS at or above $15,000,000 for 10 consecutive business days before April 27, 2026. Actual outcomes depend on market valuation dynamics and public float. If unmet, options include appeal or transfer to the Nasdaq Capital Market, subject to that market’s standards and an application fee.

Key milestones are the 10-day compliance window and the final cure deadline on April 27, 2026. Any company actions cited are evaluative; the filing lists no specific transactions. The notice introduces listing risk until compliance is confirmed.

false 0001859807 0001859807 2025-10-27 2025-10-27 0001859807 dei:FormerAddressMember 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 27, 2025

 

PROFUSA, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41177   86-3437271
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

626 Bancroft Way, Suite A

Berkeley, CA 94710

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (925) 997-6925

 

345 Allerton Ave.

South San Francisco, California 94080

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   PFSA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

On October 27, 2025, Profusa, Inc. (the “Company”) received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirement to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 for the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C). Nasdaq’s determination was based on the Company’s MVPHS having been below $15,000,000 for the prior 30 consecutive business days from September 12, 2025 through October 24, 2025.

 

The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market, and the Company’s common stock will continue to trade under the symbol “PFSA” during the compliance period.

 

In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until April 27, 2026, to regain compliance with the MVPHS requirement. If at any time before April 27, 2026, the Company’s MVPHS closes at or above $15,000,000 for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance.

 

If the Company does not regain compliance by April 27, 2026, Nasdaq will notify the Company that its common stock is subject to delisting from the Nasdaq Global Market. In such event, the Company would be entitled to appeal the delisting determination to a Nasdaq Hearings Panel. Alternatively, the Company may consider applying to transfer the listing of its securities to The Nasdaq Capital Market, subject to meeting the applicable standards for continued listing on that market and paying the required application fee.

 

The Company intends to actively evaluate and monitor its MVPHS and evaluate available options to regain compliance within the compliance period.

 

This report is being filed to comply with Nasdaq Listing Rule 5810(b), which requires prompt public disclosure of receipt of a deficiency notice.

 

Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Specifically, the Company’s statements regarding its intent and ability to regain compliance with Nasdaq’s continued listing requirements, potential actions to regain compliance, the possible transfer of the Company’s listing to The Nasdaq Capital Market, and the continued listing of the Company’s securities on Nasdaq, and other similar statements are forward-looking statements. These statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual outcomes to differ materially from those expressed or implied by such forward-looking statements, including the Company’s ability to improve or sustain its market value of publicly held shares for the requisite period, market conditions, and the Company’s financial and operating performance. These and other risks are described more fully in the Company’s other filings with the Securities and Exchange Commission, including the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents the Company files with the Securities and Exchange Commission from time to time. The Company undertakes no obligation to update forward-looking statements, except as required by law.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

October 31, 2025 Profusa, Inc.
     
  By: /s/ Ben Hwang
  Name:  Ben Hwang
  Title: Chief Executive Officer

 

 

2

 

 

FAQ

What did Profusa (PFSA) announce regarding its Nasdaq listing?

Profusa reported a Nasdaq notice that it is not in compliance with the Global Market’s MVPHS requirement of $15,000,000.

Does the Nasdaq notice immediately affect trading of PFSA shares?

No. The notice has no immediate effect; PFSA will continue to trade on the Nasdaq Global Market during the compliance period.

What is the deadline for Profusa to regain compliance?

Profusa has 180 calendar days, until April 27, 2026, to regain compliance with the MVPHS requirement.

How can Profusa regain compliance with Nasdaq’s MVPHS rule?

If MVPHS closes at or above $15,000,000 for 10 consecutive business days before April 27, 2026, Nasdaq will confirm compliance.

What happens if Profusa does not regain compliance by the deadline?

Nasdaq may initiate delisting. Profusa could appeal or consider a transfer to the Nasdaq Capital Market, subject to meeting its standards.

Why did Nasdaq issue the deficiency notice to Profusa?

Nasdaq observed Profusa’s MVPHS was below $15,000,000 for 30 consecutive business days from September 12, 2025 through October 24, 2025.
Profusa Inc

NASDAQ:PFSA

PFSA Rankings

PFSA Latest News

PFSA Latest SEC Filings

PFSA Stock Data

5.68M
29.51M
37.1%
0.38%
4.53%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK